CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 384 | US | RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo | Reata, a wholly owned subsidiary of Biogen | Diabetic Peripheral Neuropathic Pain | 08/26 | 08/26 | | |